IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients
Top Cited Papers
Open Access
- 15 March 2006
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 107 (6), 2409-2414
- https://doi.org/10.1182/blood-2005-06-2399
Abstract
Interleukin-2 (IL-2) is historically known as a T-cell growth factor. Accumulating evidence from knockout mice suggests that IL-2 is crucial for theKeywords
This publication has 28 references indexed in Scilit:
- Coexpression of CD25 and CD27 identifies FoxP3+ regulatory T cells in inflamed synoviaThe Journal of Experimental Medicine, 2005
- Regulatory T-cell therapy: is it ready for the clinic?Nature Reviews Immunology, 2005
- Regulatory T Cell Lineage Specification by the Forkhead Transcription Factor Foxp3Immunity, 2005
- Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cellsInternational Immunology, 2004
- Tolerance, not immunity, crucially depends on IL-2Nature Reviews Immunology, 2004
- Human CD4+CD25+ regulatory T cellsSeminars in Immunology, 2004
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Interleukin 2 Signaling Is Required for CD4+ Regulatory T Cell FunctionThe Journal of Experimental Medicine, 2002
- Phenotypic and Functional Separation of Memory and Effector Human CD8+ T CellsThe Journal of Experimental Medicine, 1997
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976